SEC-sourced researchBeta
SLNCF
Silence Therapeutics plc
Company comparison ↗
Data passport
- CIK
- 0001479615
- Exchange
- OTC
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Mar 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 31,643,000.0000 | Mar 5, 2026 |
| December 2024 | 43,258,000.0000 | Mar 5, 2026 |
| December 2025 | 559,000.0000 | Mar 5, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 559,000.0000 | -88,612,000.0000 | -62,271,000.0000 | 131,442,000.0000 | 69,138,000.0000 | Mar 5, 2026 |
| December 2024 | 43,258,000.0000 | -45,309,000.0000 | -67,640,000.0000 | 202,635,000.0000 | 68,612,000.0000 | Mar 5, 2026 |
| December 2023 | 31,643,000.0000 | — | — | — | — | Mar 5, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $559K | December 2025 | Mar 5, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $43.26M | December 2024 | Mar 5, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$88.61M | December 2025 | Mar 5, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$62.27M | December 2025 | Mar 5, 2026 | 10-K |
| Total assetsAssets | $131.44M | December 2025 | Mar 5, 2026 | 10-K |
| Total liabilitiesLiabilities | $69.14M | December 2025 | Mar 5, 2026 | 10-K |